Early recurrence in IPMN-derived pancreatic cancer is predictable.

In an international multicenter study, early recurrence in resected intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic cancer was identified at 10.5 months. Among 381 patients, 42% experienced recurrence, with 38% classified as early recurrences. Key predictors included CA19-9 levels and N2 disease staging. The study stratified patients into low, intermediate, and high-risk groups, revealing that adjuvant chemotherapy improved overall survival solely for high-risk patients, underscoring the need for targeted treatment strategies.